TrialCancer2020

A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.

Caitlyn T Solem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.